Aclaris reports Q2 2026 results, ATI-052 Phase 1a data and reaffirmed timelines
Aclaris says cash of $170.6 million plus a recent $40.2 million stock sale should fund operations through the end of 2028 as multiple readouts approach.
SEC filing
Latest
2 stories
Thursday, August 6
Aclaris amends at-the-market stock sale agreement with Leerink, Cantor
Aclaris Therapeutics restated its equity sales pact on August 6, 2026, replacing a February 2025 deal that had covered up to $100 million in shares.
SEC filing